NASDAQ:ERYP Erytech Pharma Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Erytech Pharma SA Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.98 +0.18 (+3.10 %) (As of 09/30/2020 03:45 AM ET) Add Compare Share Today's Range$5.98Now: $5.98▼$5.9850-Day Range$5.70MA: $6.80▼$7.7452-Week Range$3.50Now: $5.98▼$13.95Volume154 shsAverage Volume4,134 shsMarket Capitalization$108.13 millionP/E RatioN/ADividend YieldN/ABeta2.24 ProfileAnalyst RatingsChartCompetitorsEarningsInstitutional OwnershipHeadlinesShort InterestSocial Media ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Erytech Pharma. Previous Next 2.1 Community Rank Outperform VotesErytech Pharma has received 156 “outperform” votes. (Add your “outperform” vote.)Underperform VotesErytech Pharma has received 219 “underperform” votes. (Add your “underperform” vote.)Community SentimentErytech Pharma has received 58.40% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Erytech Pharma and other stocks. Vote “Outperform” if you believe ERYP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ERYP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldErytech Pharma does not currently pay a dividend.Dividend GrowthErytech Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Erytech Pharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 7.24% of the stock of Erytech Pharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Erytech Pharma are expected to grow in the coming year, from ($2.63) to ($2.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Erytech Pharma is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Erytech Pharma is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErytech Pharma has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ERYP Previous Symbol CUSIPN/A CIKN/A Webwww.erytech.com Phone33-4-78-74-44-38Debt Debt-to-Equity Ratio0.15 Current Ratio4.10 Quick Ratio4.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.34 per share Price / Book1.12Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees172 Outstanding Shares18,082,000Market Cap$108.13 million Next Earnings DateN/A OptionableNot Optionable $5.98 +0.18 (+3.10 %) (As of 09/30/2020 03:45 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ERYP News and Ratings via Email Sign-up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter. Erytech Pharma (NASDAQ:ERYP) Frequently Asked Questions How has Erytech Pharma's stock price been impacted by Coronavirus? Erytech Pharma's stock was trading at $5.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ERYP shares have increased by 14.1% and is now trading at $5.98. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Erytech Pharma? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erytech Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Erytech Pharma. Are investors shorting Erytech Pharma? Erytech Pharma saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 500 shares, an increase of 25.0% from the August 31st total of 400 shares. Based on an average daily volume of 3,700 shares, the short-interest ratio is currently 0.1 days. View Erytech Pharma's Short Interest. Who are some of Erytech Pharma's key competitors? Some companies that are related to Erytech Pharma include Voyager Therapeutics (VYGR), Rubius Therapeutics (RUBY), Orchard Therapeutics (ORTX), Harpoon Therapeutics (HARP), Freeline Therapeutics (FRLN), PDL BioPharma (PDLI), Proteon Therapeutics (PRTO), Sutro Biopharma (STRO), Cellular Biomedicine Group (CBMG), Prevail Therapeutics (PRVL), Precision BioSciences (DTIL), Cardiff Oncology (CRDF), Innate Pharma (IPHA), Innate Pharma (IPHYF) and Jounce Therapeutics (JNCE). View all competitors. What other stocks do shareholders of Erytech Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Erytech Pharma investors own include Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Sesen Bio (SESN), Cidara Therapeutics (CDTX), Fate Therapeutics (FATE), Gilead Sciences (GILD), MEI Pharma (MEIP), Verastem (VSTM) and ACADIA Pharmaceuticals (ACAD). Who are Erytech Pharma's key executives? Erytech Pharma's management team includes the following people: Mr. Gil Beyen, Chairman & CEO (Age 57)Mr. Jérôme Bailly Pharm.D., VP, Director of Pharmaceutical Operations & Deputy GM (Age 40)Mr. Eric Soyer, CFO & COO (Age 53)Dr. Alexander Scheer, Chief Scientific Officer (Age 57)Naomi Eichenbaum, Director Investor Relations When did Erytech Pharma IPO? (ERYP) raised $125 million in an initial public offering on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF acted as the underwriters for the IPO and JMP Securities was co-manager. What is Erytech Pharma's stock symbol? Erytech Pharma trades on the NASDAQ under the ticker symbol "ERYP." How do I buy shares of Erytech Pharma? Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Erytech Pharma's stock price today? One share of ERYP stock can currently be purchased for approximately $5.98. How big of a company is Erytech Pharma? Erytech Pharma has a market capitalization of $108.13 million. The company earns $-70,180,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Erytech Pharma employs 172 workers across the globe. What is Erytech Pharma's official website? The official website for Erytech Pharma is www.erytech.com. How can I contact Erytech Pharma? Erytech Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The company can be reached via phone at 33-4-78-74-44-38 or via email at [email protected] This page was last updated on 9/30/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
